Investor Relations

You are here

The Investor Relations department represents MorphoSys and its equity story to the financial market and supports the Company's overall strategic communication. Through active, reliable and transparent investor relations work, the aim is to enable MorphoSys's investors to make a realistic assessment of the Company.


24/01/2022
MorphoSys ranked Number One in Germany for Female Representation at...
10/01/2022
MorphoSys To Present At the 40th Annual J.P. Morgan Healthcare Conference
07/01/2022
MorphoSys Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022...


Wed
16
'22
Mar

Year-End Results 2021

Wed
04
'22
May

First Quarter Interim Statement 2022

Wed
18
'22
May

Annual General Meeting 2022

Wed
03
'22
Aug

Half-Year Report 2022

Wed
16
'22
Nov

Third Quarter Interim Statement 2022

Date
Title
Add to Calendar
  1. 03/16/2022

    Year-End Results 2021

  2. 05/04/2022

    First Quarter Interim Statement 2022

  3. 05/18/2022

    Annual General Meeting 2022

  4. 08/03/2022

    Half-Year Report 2022

  5. 11/16/2022

    Third Quarter Interim Statement 2022


Annual General Meeting



Investor Contact

Dr. Julia Neugebauer

Senior Director Investor Relations

Phone: +49 89 89927 179

Email Contact
LinkedIn-Profile

Myles Clouston

Senior Director, Head of US Investor Relations

Phone: +1 857 772 0240

Email Contact